☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
bristol myers squibb
BMS Reports Data from the P-III (YELLOWSTONE) Study of Zeposia to Treat Moderate to Severe Active Crohn’s Disease
April 2, 2024
BMS Reports Results from the P-III (KRYSTAL-12) Study of Krazati for the Treatment of Non-Small Cell Lung Cancer
March 29, 2024
BMS’ P-III (CheckMate -8HW) Study of Opdivo (nivolumab) + Yervoy (ipilimumab) for MSI-H/dMMR mCRC Attains Primary Endpoint
December 8, 2023
BMS’ Abecma (idecabtagene vicleucel) Receives sNDA Approval as Early Lines of Therapy for R/R Multiple Myeloma (RRMM) in Japan
December 7, 2023
Gina Fusaro, VP, Development Program Lead at BMS Shares her Views on the Acceptance of sBLA by the US FDA and the EMA Validation o...
May 17, 2023
PharmaShots' Key Highlights of First Quarter 2023
April 3, 2023
Load more...
Back to Home